Replies to post #373384 on Amarin Corp Plc (AMRN)

[couldbebetter]

Caddiedad, Thanks for posting this. I hope Denner understands what the
implications of positive results would be. If so, perhaps he would be
capable of explaining it to a potential BP acquirer. As far as the US
is concerned, unless Pfizer owns Vascepa, the US health authorities
will not care.

[Whalatane]

Caddie Theres no way IMHO that Kaiser added a generic V arm . Doing so is a major change in the trial design and would have been noted on clinical trials.gov .
I also think that almost everyone is on some Statin therapy . This is an ASCVD population , mostly prior event I believe .....Statin therapy would be SOC ( standard of care ) .
Enrollment data published
36% have had an MI
42% have had a PCI ( stents )
16% have had bypass surgery ( CABG )
13% a stroke
These are high risk patients ....mean age 69 yrs old
Yes there is no TG level requirement

Kiwi

[ORBAPU]

I believe Kaiser is funding and running Mitigate. I don’t think Amarin (KP) has any say in how the trial is run.